Search hospitals > New Hampshire > Manchester

Solinsky Center for Cancer Care

Claim this profile
Manchester, New Hampshire 03103
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Prostate Cancer
146 reported clinical trials
2 medical researchers
Photo of Solinsky Center for Cancer Care in ManchesterPhoto of Solinsky Center for Cancer Care in ManchesterPhoto of Solinsky Center for Cancer Care in Manchester

Summary

Solinsky Center for Cancer Care is a medical facility located in Manchester, New Hampshire. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Prostate Cancer and other specialties. Solinsky Center for Cancer Care is involved with conducting 146 clinical trials across 141 conditions. There are 2 research doctors associated with this hospital, such as Douglas Weckstein, MD and Ali Fleury, MD.

Area of expertise

1Cancer
Global Leader
Solinsky Center for Cancer Care has run 44 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
Solinsky Center for Cancer Care has run 34 trials for Breast Cancer. Some of their research focus areas include:
ER positive
Stage IV
HER2 negative

Top PIs

Clinical Trials running at Solinsky Center for Cancer Care

Breast Cancer
Prostate Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Anal Squamous Cell Carcinoma
Rectal Cancer
Bladder Cancer
Squamous Cell Carcinoma
Anal Cancer
Image of trial facility.

Omitting Radiation Therapy

for Breast Cancer

This study is evaluating whether a type of radiation therapy may help prevent breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Solinsky Center for Cancer Care?
Solinsky Center for Cancer Care is a medical facility located in Manchester, New Hampshire. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Prostate Cancer and other specialties. Solinsky Center for Cancer Care is involved with conducting 146 clinical trials across 141 conditions. There are 2 research doctors associated with this hospital, such as Douglas Weckstein, MD and Ali Fleury, MD.